Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesENvue Medical Inc.

ENvue Medical Inc.

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.21 USD -0.05 ( 19.23%)
Last update at 2026-11-06T19:51:00Z
VOLUME
46
Market Cap
4.96M

Momentum Score

…

ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Arlington Heights, Illinois.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.21
Low
0.21
High
52 Week Price Range
0.99
Low
62.39
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ENVue Medical Inc. is a publicly listed medical device company; widely available public detail on its specific products and operations is limited. Long-term growth drivers may include aging populations, rising demand for device-led clinical care, and successful commercialization and clinical adoption of any proprietary technologies, which could support revenue expansion. Investors may find the company attractive for exposure to the medtech sector if it appears positioned to convert clinical validation into recurring sales.

Material risks include regulatory and reimbursement uncertainty, strong competition from established medical-technology firms, execution and commercialization risk, and potential need for additional financing.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.26
Dividend Yield
-
Revenue TTM
2.55M
Revenue Per Share
4.06
Gross Profit TTM
0.15M
Debt / Equity
0.04
ROE
-106.58%
Net Debt
-3.03M
ROCE
-34.05%
Diluted EPS TTM
-26.69

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -18.49M -3.69M -3.68M -5.41M -14.25M
Net income -18.18M -3.71M -3.71M -5.45M -14.28M
Selling general administrative 7.63M 3.46M 3.92M 3.93M 5.06M
Selling and marketing expenses 2.49M 0.72M 0.86M 0.96M 1.10M
Gross profit 0.15M 1.51M 1.54M 0.17M 0.77M
Reconciled depreciation 0.90M 0.00M 0.00M 0.00M 0.00M
Ebit -11.73M -3.69M -3.44M -5.41M -14.25M
Ebitda -10.84M -3.69M -3.44M -5.41M -14.25M
Depreciation and amortization 0.90M 0.00M 0.00M 0.00M 0.00M
Operating income -11.73M -3.58M -3.44M -5.01M -5.68M
Other operating expenses 14.29M 6.14M 5.72M 5.76M 7.38M
Interest expense - 0.14M 0.25M 0.35M 0.00M
Tax provision -0.31M 0.02M 0.03M 0.04M 0.03M
Net interest income 4.40M -0.10M -0.25M -0.40M -0.05M
Income tax expense -0.31M 0.02M 0.03M 0.04M 0.03M
Total revenue 2.55M 2.56M 2.28M 0.75M 1.70M
Total operating expenses 11.89M 5.09M 4.97M 5.18M 6.45M
Cost of revenue 2.40M 1.05M 0.75M 0.58M 0.93M
Total other income expense net -6.76M -0.10M -0.25M -0.40M -8.57M
Net income from continuing ops -18.18M -3.71M -3.71M -5.45M -14.28M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 41.12M 3.63M 6.67M 5.88M 8.62M
Intangible assets 4.38M - - - -
Other current assets 0.17M 0.12M 0.05M 0.61M 0.17M
Total liab 7.63M 3.00M 2.69M 2.65M 2.31M
Total stockholder equity 33.50M 0.63M 3.99M 3.23M 6.31M
Other current liab 4.48M 2.61M 2.27M 2.15M 1.72M
Common stock 0.00M 0.00M 0.00M 0.00M 0.03M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -90.48M -69.80M -66.10M -62.38M -56.94M
Good will 29.08M 0.00M - - -
Cash 4.22M 0.75M 3.28M 2.71M 7.74M
Total current liabilities 6.66M 2.72M 2.45M 2.32M 1.90M
Current deferred revenue 0.17M 0.01M 0.05M 0.02M 0.04M
Net debt -3.03M -0.64M -3.28M -2.63M -7.69M
Short term debt 1.17M 0.05M 0.01M 0.08M 0.05M
Short long term debt 1.08M - - - -
Short long term debt total 1.20M 0.12M 0.01M 0.08M 0.05M
Other stockholder equity 124.06M 70.50M 70.15M 65.63M 63.16M
Total current assets 7.27M 3.33M 6.49M 5.61M 8.34M
Net receivables 0.54M 0.27M 0.42M 0.11M 0.26M
Inventory 2.34M 2.19M 2.73M 2.17M 0.17M
Accounts payable 0.72M 0.05M 0.14M 0.07M 0.09M
Accumulated other comprehensive income -0.08M -0.08M -0.07M -0.02M 0.06M
Non currrent assets other 0.14M 0.17M 0.17M 0.18M 0.23M
Non current assets total 33.85M 0.30M 0.19M 0.27M 0.28M
Capital lease obligations 0.12M 0.12M 0.01M 0.08M 0.05M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total cashflows from investing activities 0.09M -0.00M -0.00M -0.00M -0.00M
Net borrowings -1.42M 0.00M - - 0.00M
Total cash from financing activities 12.79M 0.00M 4.22M 2.09M 4.58M
Net income -18.18M -3.71M -3.71M -5.45M -14.28M
Change in cash 3.50M -2.53M 0.57M -5.02M 0.20M
Begin period cash flow 0.75M 3.28M 2.71M 7.74M 7.53M
End period cash flow 4.25M 0.75M 3.28M 2.71M 7.74M
Total cash from operating activities -9.37M -2.52M -3.60M -7.04M -4.37M
Issuance of capital stock 19.09M 0.00M 4.21M 2.09M 0.00M
Depreciation 0.90M 0.00M 0.00M 0.00M 0.00M
Change to inventory 0.25M 0.54M -0.56M -2.00M -0.03M
Change to account receivables -0.28M 0.22M -0.31M 0.19M -0.17M
Sale purchase of stock -5.00M 0.00M - - -
Other cashflows from financing activities 0.01M - - - -0.39M
Capital expenditures 0.06M 0.00M 0.00M 0.00M 0.00M
Change in working capital 1.66M 0.73M -0.32M -2.31M -0.49M
Stock based compensation 0.00M 0.36M 0.29M 0.35M 0.38M
Other non cash items 6.62M 0.10M 0.14M 0.36M 10.03M
Free cash flow -9.43M -2.52M -3.60M -7.04M -4.37M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FEED
ENvue Medical Inc.		 -0.05
19.23%		 0.21 - - 1.94 0.15 0.76 0.43
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

ENvue Medical Inc.

ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Arlington Heights, Illinois.

762 W. Algonquin Road, Arlington Heights, IL, United States, 60005

914 233 3004

https://envuemed.com

31

Name Title Year Born
Dr. Doron Robert Besser M.D. CEO, President & Director 1969
Ms. Rita Silberberg Executive VP of Finance, Chief Accounting Officer & Corporate Secretary 1975
Ms. Lindsey Harrison Vice President of Sales NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…